Epigenetics of fragile X syndrome and fragile X-related disorders
- PMID: 30084485
- DOI: 10.1111/dmcn.13985
Epigenetics of fragile X syndrome and fragile X-related disorders
Abstract
The fragile X mental retardation 1 gene (FMR1)-related disorder fragile X syndrome (FXS) is the most common heritable form of cognitive impairment and the second most common cause of comorbid autism. FXS usually results when a premutation trinucleotide CGG repeat in the 5' untranslated region of the FMR1 gene (CGG 55-200) expands over generations to a full mutation allele (CGG >200). This expansion is associated with silencing of the FMR1 promoter via an epigenetic mechanism that involves DNA methylation of the CGG repeat and the surrounding regulatory regions. Decrease in FMR1 transcription is associated with loss of the FMR1 protein that is needed for typical brain development. The past decade has seen major advances in our understanding of the genetic and epigenetic processes that underlie FXS. Here we review these advances and their implications for diagnosis and treatment for individuals who have FMR1-related disorders. WHAT THIS PAPER ADDS: Improved analysis of DNA methylation allows better epigenetic evaluation of the fragile X gene. New testing techniques have unmasked interindividual variation among children with fragile X syndrome. New testing methods have also detected additional cases of fragile X.
© 2018 Mac Keith Press.
Similar articles
-
Epigenetic characterization of the FMR1 gene and aberrant neurodevelopment in human induced pluripotent stem cell models of fragile X syndrome.PLoS One. 2011;6(10):e26203. doi: 10.1371/journal.pone.0026203. Epub 2011 Oct 12. PLoS One. 2011. PMID: 22022567 Free PMC article.
-
CGG-repeat dynamics and FMR1 gene silencing in fragile X syndrome stem cells and stem cell-derived neurons.Mol Autism. 2016 Oct 6;7:42. doi: 10.1186/s13229-016-0105-9. eCollection 2016. Mol Autism. 2016. PMID: 27713816 Free PMC article.
-
The FMR1 promoter is selectively hydroxymethylated in primary neurons of fragile X syndrome patients.Hum Mol Genet. 2016 Nov 15;25(22):4870-4880. doi: 10.1093/hmg/ddw311. Hum Mol Genet. 2016. PMID: 28173181 Free PMC article.
-
DNA Methylation, Mechanisms of FMR1 Inactivation and Therapeutic Perspectives for Fragile X Syndrome.Biomolecules. 2021 Feb 16;11(2):296. doi: 10.3390/biom11020296. Biomolecules. 2021. PMID: 33669384 Free PMC article. Review.
-
Human pluripotent stem cell models of Fragile X syndrome.Mol Cell Neurosci. 2016 Jun;73:43-51. doi: 10.1016/j.mcn.2015.11.011. Epub 2015 Nov 27. Mol Cell Neurosci. 2016. PMID: 26640241 Free PMC article. Review.
Cited by
-
Roles of Epigenetics and Glial Cells in Drug-Induced Autism Spectrum Disorder.Biomolecules. 2024 Apr 3;14(4):437. doi: 10.3390/biom14040437. Biomolecules. 2024. PMID: 38672454 Free PMC article. Review.
-
Fragile X Syndrome in children.Colomb Med (Cali). 2023 May 20;54(2):e4005089. doi: 10.25100/cm.v54i2.5089. eCollection 2023 Apr-Jun. Colomb Med (Cali). 2023. PMID: 37664646 Free PMC article. Review.
-
R-LOOPs on Short Tandem Repeat Expansion Disorders in Neurodegenerative Diseases.Mol Neurobiol. 2023 Dec;60(12):7185-7195. doi: 10.1007/s12035-023-03531-4. Epub 2023 Aug 4. Mol Neurobiol. 2023. PMID: 37540313 Review.
-
Phenotypic variability to medication management: an update on fragile X syndrome.Hum Genomics. 2023 Jul 7;17(1):60. doi: 10.1186/s40246-023-00507-2. Hum Genomics. 2023. PMID: 37420260 Free PMC article. Review.
-
Targeted DNA Demethylation: Vectors, Effectors and Perspectives.Biomedicines. 2023 Apr 30;11(5):1334. doi: 10.3390/biomedicines11051334. Biomedicines. 2023. PMID: 37239005 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
